logo
$1.15 Bn Market to Double by 2032, Fueled by Non-Invasive GI Diagnostics

$1.15 Bn Market to Double by 2032, Fueled by Non-Invasive GI Diagnostics

Yahoo5 days ago
The global Robotic Capsule Endoscopes (RCEs) Market is set to grow from USD 1.15 billion in 2024 to USD 2.40 billion by 2032, at a CAGR of 9.63%. This growth is due to rising GI tract disorder diagnoses, a demand for non-invasive diagnostics, and advances in AI and capsule technology.
Robotic Capsule Endoscopes (RCEs) Market
Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The "Robotic Capsule Endoscopes (RCEs) Market Outlook 2025-2034: Market Share, and Growth Analysis By Product Type (Wireless RCEs, Wired RCEs), By Technology, By Application, By End User" has been added to ResearchAndMarkets.com's offering.
The global Robotic Capsule Endoscopes (RCEs) market is poised for remarkable growth, with an estimated size of USD 1.15 billion in 2024, projected to reach USD 2.40 billion by 2032 at a CAGR of 9.63%.
This surge is driven by the growing adoption of non-invasive diagnostic technologies to treat gastrointestinal (GI) disorders. RCEs represent a transformative advancement, equipped with micro-cameras, sensors, and robotics for controlled navigation and imaging of the GI tract. As manufacturers focus on innovations such as magnetic control systems and AI-based lesion detection, the industry is overcoming traditional limitations. However, challenges like high costs and regulatory complexities persist.
Recent market developments spotlight AnX Robotica's magnetically controlled capsule systems introduced in the US, Olympus's prototypes with enhanced imaging capabilities, and Check-Cap's progress in X-ray-based colon imaging capsules. The convergence of these technologies is paving the way for precision diagnostics in GI healthcare.
Market dynamics are shaped by several key trends and drivers. The demand for non-invasive procedures and technological advancements in capsule miniaturization are catalysts for growth. On the other hand, the high cost of devices and regulatory hurdles remain barriers. Despite these challenges, companies are making strides in enhancing control systems, integrating AI for real-time diagnostics, and expanding the applications beyond small bowel imaging.
The comprehensive market report provides insights into the competition, identifying strategies for increased sales and market share. With input from industry leaders, the report explores the economic impacts, technological advancements, and tailored strategies that are crucial for navigating the evolving RCEs market landscape.
Further analysis includes an exploration of consumer preferences, including buying patterns and decision-making factors, coupled with insights into the regulatory environment's influence on industry growth. The RCEs market report is a valuable resource for understanding consumer behavior and navigating economic shifts.
Key Highlights of the Report:
Global and regional market size projections from 2024 to 2034.
Analysis of market segments, trends, and opportunities.
Competitive landscape insights, featuring leading companies.
Impact of economic factors, supply chain disruptions, and regulatory issues on market dynamics.
Comprehensive data on consumer behavior, brand preferences, and buying patterns.
Key Questions Addressed:
Current and future market size at various levels.
Market penetration of different types and applications.
Impact of economic trends and geopolitical issues on market forecasts.
Regional market opportunities and high-performing products.
Key drivers, challenges, and competitive intelligence.
Key Attributes:
Report Attribute
Details
No. of Pages
150
Forecast Period
2024 - 2032
Estimated Market Value (USD) in 2024
$1152 Million
Forecasted Market Value (USD) by 2032
$2403.7 Million
Compound Annual Growth Rate
9.6%
Regions Covered
Global
Companies Featured
Medtronic plc
IntroMedic Co., Ltd.
CapsoVision, Inc.
Check-Cap Ltd.
Olympus Corporation
AnX Robotica Corp.
Jinshan Science & Technology Co., Ltd.
RF Co., Ltd.
Chongqing Jinshan Science & Technology Group
Siemens Healthineers AG
Fujifilm Holdings Corporation
BodyCap
Pentax Medical (HOYA Corporation)
OMOM Capsule Endoscopy
Jinshan North America
For more information about this report visit https://www.researchandmarkets.com/r/jeug70
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Robotic Capsule Endoscopes (RCEs) Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Rising Defense Partner Reacts After Trump Threat
Rising Defense Partner Reacts After Trump Threat

Newsweek

timea minute ago

  • Newsweek

Rising Defense Partner Reacts After Trump Threat

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. India has hit back at the United States in defense of its oil purchases from Russia after President Donald Trump issued a new threat of tariffs tied to the trade. The U.S. State Department did not immediately respond to a request for comment outside of office hours. Why It Matters The increasing friction between India and the United States is in part an indication of the failure to reach a trade deal between the Trump administration and the world's most populous country and fastest growing top economy. Increasingly friendly U.S. relations with Indian rival Pakistan have been another irritant in the relationship. But it also highlights a souring in a relationship that is key for global security, with India seen as a potential bulwark against China for the United States while pursuing a foreign policy that had traditionally been strongly independent. What To Know Trump issued a new threat of tariffs on India on Monday, linking it to India's purchases of Russian oil. It came at a time when Trump was seeking to increase pressure on Russia over its war in Ukraine, which has only increased in intensity despite the president's pledge to end it as soon as he took office. The Indian national flag waves on National Flag Day, July 22, 2025, in front of the Tripura State Museum, Ujjayanta Palace, in Agartala. The Indian national flag waves on National Flag Day, July 22, 2025, in front of the Tripura State Museum, Ujjayanta Palace, in Agartala. Photo by ABHISEK SAHA/Middle East Images/AFP via Getty Images India's External Affairs Ministry said in a statement that its purchases of oil from Russia were a necessity compelled by the state of the global market. It challenged criticism over the oil deals from both the United States and European Union. "It is revealing that the very nations criticizing India are themselves indulging in trade with Russia. Unlike our case, such trade is not even a vital national compulsion," the statement from the ministry spokesperson said. "Where the United States is concerned, it continues to import from Russia uranium hexafluoride for its nuclear industry, palladium for its EV industry, fertilizers as well as chemicals." Ukraine Invasion New Delhi said Washington had encouraged it to buy Russian oil after the invasion of Ukraine in 2022 to stabilize the global energy market. It also said the EU's trade with Russia had been significantly bigger than India's. Russia has continued to make billions from energy exports despite Western sanctions to try to apply pressure over the Ukraine war. "Europe-Russia trade includes not just energy, but also fertilizers, mining products, chemicals, iron and steel and machinery and transport equipment," it said. "The targeting of India is unjustified and unreasonable. Like any major economy, India will take all necessary measures to safeguard its national interests and economic security." In the absence of a trade deal with the United States, India has meanwhile been pursuing other agreements and strengthening its ties with China. What People Are Saying U.S. President Donald Trump on Truth Social: "India is not only buying massive amounts of Russian Oil, they are then, for much of the Oil purchased, selling it on the Open Market for big profits. They don't care how many people in Ukraine are being killed by the Russian War Machine. Because of this, I will be substantially raising the Tariff paid by India to the USA. Thank you for your attention to this matter!!! President DJT" India's Ministry of External Affairs spokesperson: "India's imports are meant to ensure predictable and affordable energy costs to the Indian consumer. They are a necessity compelled by global market situation. However, it is revealing that the very nations criticizing India are themselves indulging in trade with Russia. Unlike our case, such trade is not even a vital national compulsion." What Happens Next India is unlikely to be swayed by U.S. pressure and in the absence of a trade deal is likely to continue to take an independent line. The worsening of the relationship between the United States and India could be to the benefit of U.S. rivals Russia and China as they also seek to cement India in their camp.

Report – Inter Milan To Meet Atalanta Demands For Nigeria Star Forward: €50M Offer Ready
Report – Inter Milan To Meet Atalanta Demands For Nigeria Star Forward: €50M Offer Ready

Yahoo

time28 minutes ago

  • Yahoo

Report – Inter Milan To Meet Atalanta Demands For Nigeria Star Forward: €50M Offer Ready

Inter Milan will soon lodge a third and probably final offer for Atalanta forward Ademola Lookman amid protracted talks. According to Gazzetta dello Sport via FCInterNews, the Serie A runners-up are ready to match La Dea's request. What initially appeared to be a routine deal has turned into a soap opera. Indeed, Inter have yet to sign Ademola Lookman despite reaching a verbal agreement with the player. Furthermore, they've already had two offers rejected by the Bergamo club. Inter Milan Ready to Meet Atalanta Asking Price for Ademola Lookman BERGAMO, ITALY – JANUARY 18: Ademola Lookman of Atalanta BC looks on during the Serie A match between Atalanta BC and SSC Napoli at Gewiss Stadium on January 18, 2025 in Bergamo, Italy. (Photo by) Atalanta turned down Inter's €45 million bid for the 27-year-old. Instead, they're continuing to ask for €50 million, making Inter's life miserable. However, Cristian Chivu could soon welcome his fifth summer signing. Indeed, the San Siro giants are reportedly willing to match Atalanta's asking price to finally bring an end to this saga. Inter's third proposal will likely include several bonuses in order to meet the desired price. Meanwhile, Lookman is waiting for the clubs to strike an agreement after expressing his desire to join Inter.

Gerresheimer to spin off moulded glass business
Gerresheimer to spin off moulded glass business

Yahoo

time28 minutes ago

  • Yahoo

Gerresheimer to spin off moulded glass business

Gerresheimer has announced plans to separate its moulded glass business following a comprehensive strategic review aimed at assessing growth opportunities and competitive positioning. The company, which serves the pharmaceutical, biotech, and cosmetic sectors, plans to initiate a sales process for this business unit. The moulded glass division, strengthened by the acquisition of Bormioli Pharma, operates eight production facilities across the Americas, Europe, and Asia. In 2024, this unit generated approximately €735m ($850.4m) in revenues, with an adjusted earnings before interest, taxes, depreciation, and amortisation margin of around 20%. As part of the integration of Bormioli Pharma, Gerresheimer is establishing the moulded glass business as a standalone entity. Further updates on this transition will be shared during the upcoming capital markets day scheduled for 15 October 2025. The combined operations provide a diverse range of glass packaging solutions, including bottles, jars, and containers, for the pharmaceutical, cosmetic, and food and beverage sectors. In addition, the acquisition has allowed Gerresheimer to expand its offerings, including primary packaging and dosing systems for pharmaceuticals while enhancing opportunities for integrating high-value plastic solutions within the industry. Gerresheimer CEO Dietmar Siemssen said: 'We see the best growth opportunities for our newly formed Moulded Glass Powerhouse outside the Gerresheimer Group. 'As part of our strategic transformation, Gerresheimer will focus even stronger on the portfolio of systems and solutions for the pharma and biotech industry.' The company has invested around €100m in upgrading its facility in Lohr am Main, Germany, by installing an energy-efficient oxy-hybrid furnace over the past two years. In December 2024, Gerresheimer announced the addition of a new syringe production hall at its site in Skopje, North Macedonia, with an investment of more than €100m. "Gerresheimer to spin off moulded glass business" was originally created and published by Packaging Gateway, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store